These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 26635234)

  • 1. Von Willebrand factor activity assay errors.
    Bowyer AE; Guy S; Shepherd MF; Sampson BM; Kitchen S; Makris M
    Haemophilia; 2016 Jan; 22(1):e74-6. PubMed ID: 26635234
    [No Abstract]   [Full Text] [Related]  

  • 2. Prospective, observational study of plasma-derived factor VIII/von Willebrand factor in immune tolerance induction: the PRISM registry.
    Kruse-Jarres R; Gilsenan A; Spears J; Kaye JA
    Haemophilia; 2015 Mar; 21(2):e122-e124. PubMed ID: 25623889
    [No Abstract]   [Full Text] [Related]  

  • 3. Cross-reacting Material-positive Hemophilia A Diagnosed in a Patient with a Spontaneous Thigh Hemorrhage.
    Saito T; Mukae J; Nakamura Y; Inaba H; Nogami K; Koyama T; Fukutake K; Yamamoto K
    Intern Med; 2017; 56(13):1719-1723. PubMed ID: 28674365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune tolerance induction with a factor VIII concentrate containing von Willebrand factor (Haemoctin SDH®) in 14 patients with severe haemophilia A.
    Bidlingmaier C; Kurnik K; Escuriola-Ettingshausen C; Jager R; Klamroth R; Male C; Marosi A; Nemes L; von Stackelberg A; Kreuz W
    Haemophilia; 2011 Sep; 17(5):e837-40. PubMed ID: 21649797
    [No Abstract]   [Full Text] [Related]  

  • 5. Novel therapies for hemophilia A - the role of the von Willebrand factor chaperone.
    Aguila S; O'Donnell JS
    J Thromb Haemost; 2019 Mar; 17(3):426-428. PubMed ID: 30652400
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment of single factor deficiencies: a case study approach.
    Marques MB
    Clin Lab Sci; 2003; 16(2):120-2. PubMed ID: 12757193
    [No Abstract]   [Full Text] [Related]  

  • 7. Similarity in joint and mucous bleeding syndromes in type 2N von Willebrand disease and severe hemophilia A coexisting with type 1 von Willebrand disease in two Chinese pedigrees.
    Qin HH; Xing ZF; Wang XF; Ding QL; Xi XD; Wang HL
    Blood Cells Mol Dis; 2014 Apr; 52(4):181-5. PubMed ID: 24351655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of factor VIII-binding capacity of endogenous von Willebrand factor in the development of factor VIII inhibitors in patients with severe hemophilia A.
    Repessé Y; Costa C; Palla R; Moshai EF; Borel-Derlon A; D'Oiron R; Rothschild C; El-Beshlawy A; Elalfy M; Ramanan V; Eshghi P; Oldenburg J; Pavlova A; Rosendaal FR; Peyvandi F; Kaveri SV; Lacroix-Desmazes S
    Haematologica; 2019 Aug; 104(8):e369-e372. PubMed ID: 30705098
    [No Abstract]   [Full Text] [Related]  

  • 9. Factor VIII deficiency diseases: an approach to laboratory diagnosis and management.
    Bhargava M
    Indian Pediatr; 1981 Nov; 18(11):787-91. PubMed ID: 6804381
    [No Abstract]   [Full Text] [Related]  

  • 10. Challenges of the management of severe hemophilia A with inhibitors: two case reports emphasizing the potential interest of a high-purity human Factor VIII/von Willebrand factor concentrate and individually tailored prophylaxis guided by thrombin-generation test.
    Mathieu S; Crampe C; Dargaud Y; Lavigne-Lissalde G; Escuriola-Ettingshausen C; Tardy B; Meley R; Thouvenin S; Stephan JL; Berger C
    Blood Coagul Fibrinolysis; 2015 Dec; 26(8):940-5. PubMed ID: 26517064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical overview of Fanhdi/Alphanate (plasma-derived, VWF-containing FVIII concentrate) in immune tolerance induction in haemophilia A patients with inhibitors.
    Jiménez-Yuste V; Oldenburg J; Rangarajan S; Kurth MH; Bozzo J; Santagostino E
    Haemophilia; 2016 Jan; 22(1):e71-4. PubMed ID: 26612826
    [No Abstract]   [Full Text] [Related]  

  • 12. Adult haemophilia A patients with inhibitors: successful immune tolerance induction with a single FVIII/VWF product.
    Rangarajan S; Jiménez-Yuste V; Santagostino E
    Haemophilia; 2014 Nov; 20(6):e414-7. PubMed ID: 25333452
    [No Abstract]   [Full Text] [Related]  

  • 13. Undetected factor VIII in a patient with type 3 von Willebrands disease mistaken as severe haemophilia A.
    Mullah-Ali AM; Chan AK; Lillicrap D; Decker K; Seroski W; Moffat K; Walker I; Pai MK
    Haemophilia; 2009 Nov; 15(6):1258-61. PubMed ID: 19563498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Von Willebrand factor, factor VIII and the factor VIII/von Willebrand factor complex.
    Ingerslev J
    Dan Med Bull; 1990 Oct; 37(5):385-406. PubMed ID: 2125548
    [No Abstract]   [Full Text] [Related]  

  • 15. First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/von Willebrand factor concentrate in an observational immune tolerance induction study.
    Kreuz W; Escuriola Ettingshausen C; Vdovin V; Zozulya N; Plyushch O; Svirin P; Andreeva T; Bubanská E; Campos M; Benedik-Dolničar M; Jiménez-Yuste V; Kitanovski L; Klukowska A; Momot A; Osmulskaya N; Prieto M; Šalek SZ; Velasco F; Pavlova A; Oldenburg J; Knaub S; Jansen M; Belyanskaya L; Walter O; ;
    Haemophilia; 2016 Jan; 22(1):87-95. PubMed ID: 26202305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acquired bleeding disorders.
    Tiede A; Zieger B; Lisman T
    Haemophilia; 2022 May; 28 Suppl 4():68-76. PubMed ID: 35521729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Wilate--the first VWF/FVIII of the second generation--newly introduced in Germany].
    Pharm Unserer Zeit; 2006; 35(1):83. PubMed ID: 16465869
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacokinetic profile of Optivate® (high-purity factor VIII/von Willebrand factor concentrate) in treating von Willebrand disease.
    Shaikh-Zaidi R; Lubetsky A; Inbal A; Dash C
    Haemophilia; 2016 Jan; 22(1):e64-7. PubMed ID: 26572507
    [No Abstract]   [Full Text] [Related]  

  • 19. Von Willebrand factor-specific antibodies developing upon treatment of FVIII-deficient mice with different FVIII preparations.
    Kallas A; Kuuse S; Maimets T; Pooga M
    Acta Haematol; 2008; 119(4):244-7. PubMed ID: 18594135
    [No Abstract]   [Full Text] [Related]  

  • 20. The von Willebrand factor from basic mechanisms to clinical practice.
    Federici AB
    Blood Transfus; 2011 May; 9 Suppl 2(Suppl 2):s1-2. PubMed ID: 21839027
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.